Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)-induced platelet CD40 ligand overexpression in rats

International Journal of Cardiology

Volumn 144, Issue 2, 2010, Pages 283-285

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a   Ueda, So ^a   Takeuchi, Masayoshi ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; CD40L; Diabetes; PEDF

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CD40 LIGAND; PIGMENT EPITHELIUM DERIVED FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; THROMBOCYTE;

EID: 77957845592     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.01.071     Document Type: Article

References (14)

1. U. Schonbeck, and P. Libby CD40 signaling and plaque instability Cir Res 89 2001 1092 1103
2. D. Vishnervetsky, V.A. Kiyanista, and P.J. Gandhi CD40 ligand: a novel target in the flight against cardiovascular disease Ann Pharmacother 38 2004 1500 1508
3. F. Mach, U. Schönbeck, G.K. Sukhova, E. Atkinson, and P. Libby Reduction of atherosclerosis in mice by inhibition of CD40 signalling Nature 394 1998 200 203
4. E. Lutgens, L. Gorelik, and M.J. Daemen Requirement of CD154 in the progression of atherosclerosis Mat Med 5 1999 1313 1316
5. K. Takenaka, S. Yamagishi, T. Matsui, K. Nakamura, and T. Imaizumi Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes Curr Neurovasc Res 3 2006 73 77
6. S. Yamagishi, K. Nakamura, T. Matsui, S. Ueda, K. Fukami, and S. Okuda Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications Expert Opin Investig Drugs 17 2008 983 996
7. J. Tombran-Tink, and C.J. Barnstable PEDF: a multifaceted neurotropic factor Nat Rev Neurosci 4 2003 628 636
8. S. Yamagishi, T. Matsui, K. Nakamura, S. Ueda, Y. Noda, and T. Imaizumi Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications Curr Drug Targets 9 2008 1025 1029
9. S. Yamagishi, K. Nakamura, and T. Matsui Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J Biol Chem 281 2006 20213 20220
10. S. Yamagishi, Y. Inagaki, S. Amano, T. Okamoto, M. Takeuchi, and Z. Makita Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end products-induced injury through its antioxidative properties Biochem Biophys Res Commun 296 2002 877 882
11. S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, and T. Imaizumi Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis Microvasc Res 72 2006 86 90
12. K. Takenaka, S. Yamagishi, and T. Matsui Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes Atherosclerosis 197 2008 25 33
13. S. Yamagishi, H. Adachi, and A. Abe Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome J Clin Endocrinol Metab 91 2006 2447 2450
14. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150